Figure 3From: Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjectsMean sputum fluid phase mediators (± SEM) at baseline before treatment with roflumilast (solid bars) or placebo (open bars), after 13 days' treatment, and 7 h and 24 h after allergen challenge. Roflumilast significantly inhibited the allergen-induced increased level of eosinophil cationic protein (ECP) and neutrophil elastase (NE) (p < 0.05).Back to article page